Crinetics Pharmaceuticals, Inc.
CRNX
$35.20
$0.732.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -74.11% | -78.00% | -71.35% | -53.93% | -15.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -74.11% | -78.00% | -71.35% | -53.93% | -15.28% |
| Cost of Revenue | 42.50% | 37.03% | 35.80% | 30.59% | 29.41% |
| Gross Profit | -45.35% | -40.53% | -39.42% | -33.25% | -31.10% |
| SG&A Expenses | 71.68% | 69.51% | 60.53% | 45.46% | 37.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.98% | 45.04% | 41.92% | 34.25% | 31.28% |
| Operating Income | -52.22% | -47.84% | -44.78% | -36.33% | -32.60% |
| Income Before Tax | -39.10% | -39.36% | -40.59% | -34.33% | -30.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.10% | -39.36% | -40.59% | -34.33% | -30.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.10% | -39.36% | -40.59% | -34.33% | -30.88% |
| EBIT | -52.22% | -47.84% | -44.78% | -36.33% | -32.60% |
| EBITDA | -51.72% | -47.54% | -44.68% | -36.39% | -32.72% |
| EPS Basic | -0.12% | -2.14% | -10.61% | -15.15% | -17.50% |
| Normalized Basic EPS | -0.11% | -2.14% | -10.62% | -15.15% | -17.50% |
| EPS Diluted | -0.23% | -2.25% | -10.73% | -15.27% | -17.34% |
| Normalized Diluted EPS | -0.11% | -2.14% | -10.62% | -15.15% | -17.50% |
| Average Basic Shares Outstanding | 39.09% | 36.42% | 27.56% | 17.04% | 11.69% |
| Average Diluted Shares Outstanding | 39.09% | 36.42% | 27.56% | 17.04% | 11.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
